Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
7.16 (1y: +57%)
Market Cap 2.36 B P/E(ttm)
Enterprise Value 2.46 B P/B 12.87
OPK- NYSE (USA)
Opko Health, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$7.16
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 1.561
OPK's Cash to Debt is ranked lower than
61% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3750.67 vs. OPK: 1.561 )
OPK' s 10-Year Cash to Debt Range
Min: 0.56   Max: No Debt
Current: 1.56
Equity to Asset 0.011
OPK's Equity to Asset is ranked lower than
85% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.53 vs. OPK: 0.011 )
OPK' s 10-Year Equity to Asset Range
Min: -0.33   Max: 0.94
Current: 0.01
-0.33
0.94
F-Score: 4
Z-Score: 3.46
M-Score: -4.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -79.20
OPK's Operating margin (%) is ranked lower than
79% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. OPK: -79.20 )
OPK' s 10-Year Operating margin (%) Range
Min: -31624.4   Max: -46.7
Current: -79.2
-31624.4
-46.7
Net-margin (%) -61.7
OPK's Net-margin (%) is ranked lower than
79% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. OPK: -61.7 )
OPK' s 10-Year Net-margin (%) Range
Min: -44561.5   Max: -4.6
Current: -61.7
-44561.5
-4.6
ROE (%) -16.2
OPK's ROE (%) is ranked lower than
72% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 4.80 vs. OPK: -16.2 )
OPK' s 10-Year ROE (%) Range
Min: -11095.8   Max: -0.8
Current: -16.2
-11095.8
-0.8
ROA (%) -10
OPK's ROA (%) is ranked lower than
73% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. OPK: -10 )
OPK' s 10-Year ROA (%) Range
Min: -678.3   Max: -0.6
Current: -10
-678.3
-0.6
ROC (Joel Greenblatt) (%) -115.90
OPK's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 14.00 vs. OPK: -115.90 )
OPK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19191.5   Max: -66.6
Current: -115.9
-19191.5
-66.6
Revenue Growth (%) 27.8
OPK's Revenue Growth (%) is ranked higher than
97% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. OPK: 27.8 )
OPK' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 93.4
Current: 27.8
0
93.4
EBITDA Growth (%) -4.9
OPK's EBITDA Growth (%) is ranked higher than
66% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. OPK: -4.9 )
OPK' s 10-Year EBITDA Growth (%) Range
Min: -60.6   Max: 33.7
Current: -4.9
-60.6
33.7
EPS Growth (%) -4.1
OPK's EPS Growth (%) is ranked higher than
62% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. OPK: -4.1 )
OPK' s 10-Year EPS Growth (%) Range
Min: -55.8   Max: 38.4
Current: -4.1
-55.8
38.4
» OPK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

OPK Guru Trades in Q2 2012

Murray Stahl 32,300 sh (+144.7%)
Mario Gabelli 15,000 sh (unchged)
Zeke Ashton 217,800 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 62,341 sh (-83.25%)
» More
Q3 2012

OPK Guru Trades in Q3 2012

Murray Stahl 40,521 sh (+25.45%)
Mario Gabelli 15,000 sh (unchged)
Jim Simons Sold Out
» More
Q4 2012

OPK Guru Trades in Q4 2012

Steven Cohen 11,123 sh (New)
Mario Gabelli 15,000 sh (unchged)
Murray Stahl 40,483 sh (-0.09%)
» More
Q1 2013

OPK Guru Trades in Q1 2013

Murray Stahl 40,761 sh (+0.69%)
Mario Gabelli 15,000 sh (unchged)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OPK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2011-03-31 Reduce -90.58%$3.48 - $4.83 $ 7.1679%15000
Mario Gabelli 2010-09-30 Add 962%$2.07 - $2.6 $ 7.16210%159300
Mario Gabelli 2010-06-30 Reduce -90%$1.87 - $2.55 $ 7.16239%15000
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Opko Health, Inc.

Top Three 'Insider Cluster' Jams
March 19, 2013
Recent GuruFocus studies show several “insider cluster” buys made in the last month. “Insider clusters” are defined as concentrated purchases or sells made by a company’s executive members at a specific time. Read more...
The Top Insider Cluster Companies in the Last Month
December 10, 2012
Jim Simons,Steven Cohen - The Top Insider Cluster Companies In The Last Month
Within the last four weeks, the companies listed below experienced either the most Insider cluster buys or Insider cluster sells. Insider clusters are known as concentrated purchases or sells that were made by a company’s executive members at a specific time. The results were taken from the Premium feature, GuruFocus Insider Cluster Buys and Sells. Read more...
Top 5 Mid-Week Insider Buys
October 10, 2012
- Top 5 Mid-Week Insider Buys
The list below represents companies that experienced the top five highest insider buying amount traded in the first half of this week. Trades are counted per single Insider transaction. Read more...

Ratios

vs
industry		 vs
history
P/B 12.87
OPK's P/B is ranked lower than
89% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. OPK: 12.87 )
OPK' s 10-Year P/B Range
Min: 0.29   Max: 50.6
Current: 12.87
0.29
50.6
P/S 31.13
OPK's P/S is ranked lower than
98% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. OPK: 31.13 )
OPK' s 10-Year P/S Range
Min: 6   Max: 535
Current: 31.13
6
535
EV-to-EBIT -69.8
OPK's EV-to-EBIT is ranked lower than
55% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 16.25 vs. OPK: -69.8 )
OPK' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -69.8

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 87.2
OPK's Price/Net Current Asset Value is ranked higher than
95% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 8.90 vs. OPK: 87.2 )
OPK' s 10-Year Price/Net Current Asset Value Range
Min: 5.8   Max: 162
Current: 87.2
5.8
162
Price/Tangible Book 785
OPK's Price/Tangible Book is ranked higher than
98% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. OPK: 785 )
OPK' s 10-Year Price/Tangible Book Range
Min: 0.3   Max: 481
Current: 785
0.3
481
Price/Median PS Value 1.1
OPK's Price/Median PS Value is ranked higher than
84% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. OPK: 1.1 )
OPK' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.8
Current: 1.1
0.3
2.8
Forward Rate of Return (Yacktman) -18.74
OPK's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. OPK: -18.74 )
OPK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.8   Max: 45.9
Current: -18.74
1.8
45.9

Business Description

Opko Health, Inc. was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc., which was later changed to eXegenics, Inc. On June 8, 2007, the Company changed its name to OPKO Health, Inc. It is a healthcare company, which is focused on the discovery, development, and commercialization of proprietary pharmaceuticals, diagnostic and imaging systems and instrumentation products for the treatment, diagnosis and management of ophthalmic diseases and conditions. The Company's business presently consists of the development of ophthalmic pharmaceuticals and the development, commercialization and sale of ophthalmic diagnostic and imaging systems and instrumentation products. It has several compounds and technologies in research and development for the ophthalmic pharmaceutical market. In July 2007, the Company initiated the first of two required pivotal Phase III trials for bevasiranib, a drug candidate in development for the treatment of Wet AMD. Bevasiranib is the first therapy in late stage clinical development based on the Nobel Prize-winning RNA interference, or RNAi technology. On March 6, 2009, following the recommendation of the Independent Data Monitoring Committee, or the IDMC, the Company determined to terminate the Phase III clinical trial of bevasiranib. It intends to continue development of its siRNA portfolio targeting Vascular Endothelial Growth Factor (VEGF), including its recently announced VEGFA165b sparing siRNA. These new proprietary siRNA's are designed to inhibit the angiogenic VEGFA165 (VEGFA165 isoform) but spare the anti-angiogenic VEGFA165b isoform. The Company is also researching and developing several novel pharmaceutical products for a range of ophthalmic diseases and conditions, including Dry AMD, diabetic retinopathy and Diabetic Macular Edema, or DME, dry eye, viral and allergic conjunctivitis, inflammation and prevention of ocular infection. The Company currently does not have pharmaceutical or diagnostics sales or marketing personnel in the United States and have limited personnel in Chile, Mexico, and Israel. In order to commercialize any pharmaceutical or diagnostic products that are approved for commercial sale, the Company must either build a sales and marketing infrastructure or collaborate with third parties with sales and marketing experience. The Company is also currently developing Aquashunt(tm), an innovative shunt device for the treatment of glaucoma, the second leading cause of blindness in the U.S. The patented Aquashunt device is intended to reduce intraocular pressure physiologically by allowing excess fluid in the eye to exit naturally. In January 2009, the Company began treating patients in a clinical trial designed to assess the safety and efficacy of the Aquashunt. The Company faces competition from competitors for its instrumentation products located in the United States and abroad, which competitors include companies with a far more diverse
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
Traded in other countries:XCY.Germany
» More Articles for OPK

Headlines

Articles On GuruFocus.com
American Insider Trades March 15-21 Mar 22 2013 
Top Three 'Insider Cluster' Jams Mar 19 2013 
The Top Insider Cluster Companies in the Last Month Dec 10 2012 
Top 5 Mid-Week Insider Buys Oct 10 2012 
Stocks with Bigest Insider Buys and Sells November 2011 Dec 01 2011 
Opko Health Inc (OPK) Vice Chairman & CTO Jane Ph D Hsiao buys 200,000 Shares Jan 25 2011 
Opko Health Inc Reports Operating Results (10-K/A) Nov 10 2010 
Opko Health Inc Reports Operating Results (10-Q) Nov 09 2010 
Opko Health Inc Reports Operating Results (10-Q) May 10 2010 
Opko Health Inc (OPK) CEO Phillip Md Et Al Frost buys 10,000 Shares Mar 25 2010 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial